About Us

Company Overview

BriSTAR Immunotech is a clinical-stage cell therapy company dedicated to the development and commercialization of innovative engineered T cell immunotherapy products for the treatment of cancer and viral infections.

BriSTAR Immunotech was founded in 2018 by internationally-renowned molecular immunologist, Dr. Lin Xin and his team at Tsinghua University.

Development history

2024

IND approval for YTS104

First case of IIT clinical reinfusion for Project 109

Undertaking the National Key Research and Development Program

2023

Submitting a new IND

Preclinical data AACR released

Two solid tumor products entered early clinical stage

2022

B+ round financing

Submitted the first IND

New CMC & QC facilities completed

2021

B-round financing

Paper on STAR-T published

IIT date presented at EHA conference

2020

A+round financing

Moved in Beijing R&D headquarter

IIT Data presented in ASH conference

2019

A-round financing

Initiated STAR-T IIT

2018

Company was founded (Dr. Lin Xin)

Angel round fiInancing

Pre-A round financing

Initiated TCR-T IIT